EUVIMEDEUVIMED entdecken
Multizentrische Studie

Eculizumab as Salvage Treatment for Thrombotic Microangiopathy After Lung Transplantation

Hernando Trujillo iD, Ana Huerta, Rodrigo Alonso, Maria Luisa Serrano, Myriam Aguilar, Enrique Morales, Teresa Cavero

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15443 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Hernando Trujillo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. Hauptthemen laut MEDLINE: Thrombotic Microangiopathies, Lung Transplantation, Antibodies, Monoclonal, Humanized, Salvage Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thrombotic microangiopathy (TMA) is a rare complication after lung transplantation (LT) that has seldom been characterized in detail. Recent evidence has linked TMA other than primary atypical hemolytic uremic syndrome (aHUS) with hyperactivation of the complement alternative pathway. The focus of this investigation was to analyze the treatment response with eculizumab in TMA after LT.

Methods

Case series where we have studied 11 patients with TMA after LT from 2 Spanish tertiary healthcare centers. Clinical data and response rates to eculizumab are provided.

Results

The main indication for lung transplant was chronic obstructive pulmonary disease (COPD) (36%) and most cases (82%) received bilateral LT. The median time to TMA diagnosis was 11.6 months (4.7–28.9) and the TMA trigger in the majority of cases (73%) was immunosuppressive drugs. Platelet and hemoglobin nadir were 58 × 10 3 /µL (24–108) and 7.7 g/dL (7.1–7.9), respectively. All cases presented acute kidney injury (AKI) with a median creatinine of 4 mg/dL (3.2–4.8) and 54.5% required acute dialysis. Eculizumab was started after a median time of 8 days (6–14) with a median duration of 3 weeks (2–8). Complete TMA response was observed in 7 (63.6%) cases and hematologic response in 10 (90.9%). The time to hematologic and renal response was 23 days (13–29) and 28 days (14–46), respectively.

Conclusions

TMA after LT is infrequent but potentially devastating. Our findings suggest that short cycles of eculizumab may be effective for severe TMA after LT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombotic MicroangiopathiesLung TransplantationAntibodies, Monoclonal, HumanizedSalvage TherapyComplement Inactivating AgentsHumansFemaleMaleMiddle AgedFollow-Up StudiesPrognosisAdultAgedPostoperative ComplicationsRetrospective StudiesRisk FactorsGraft RejectionKidney Function TestsGraft Survival

Stichwörter der Autor:innen

complement biologykidney failure/injurylung (allograft) function/dysfunction

Substanzen

eculizumabAntibodies, Monoclonal, HumanizedComplement Inactivating Agents

Autor:innen und Institutionen

  • Nephrology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Nephrology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Pneumology Department, Lung Transplant Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Pneumology Department, Lung Transplant Unit, Hospital Universitario Puerta de Hierro, Madrid, Spain.

ORCID-Profile: Hernando Trujillo

Zitieren

APA

Trujillo, H., Huerta, A., Alonso, R., Serrano, M. L., Aguilar, M., Morales, E., & Cavero, T. (2024). Eculizumab as Salvage Treatment for Thrombotic Microangiopathy After Lung Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.15443

Vancouver

Trujillo H, Huerta A, Alonso R, Serrano ML, Aguilar M, Morales E, et al. Eculizumab as Salvage Treatment for Thrombotic Microangiopathy After Lung Transplantation. Clinical Transplantation. 2024. doi:10.1111/ctr.15443

BibTeX
@article{Trujillo2024,
  author = {Trujillo, Hernando and Huerta, Ana and Alonso, Rodrigo and Serrano, Maria Luisa and Aguilar, Myriam and Morales, Enrique and Cavero, Teresa},
  title = {Eculizumab as Salvage Treatment for Thrombotic Microangiopathy After Lung Transplantation},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15443}
}
Kostenlos starten →